SCHEMBL609929

SCHEMBL609929

C#CC(O)(c1ccccc1)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
CYP2D6 P10635 1/20 0.43
HRH1 P35367 1/20 0.43
SCN1A P35498 1/20 0.43
KMT2A Q03164 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
CHRM3 P20309 10/20 0.40
CHRM2 P08172 9/20 0.40
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6589615 0.92 KEAP1 (0.47) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL4889259 0.92 KEAP1 (0.51) CYP2D6HRH1MAPTNPSR1KEAP1
SCHEMBL9193099 0.91 MAPT (0.52) CYP2D6HRH1MAPTNPSR1KEAP1
SCHEMBL552275 0.81 MEN1 (0.36) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL22461931 0.78 CYP2D6 (0.50) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL9037625 0.77 CYP19A1 (0.43) MEN1LMNAKMT2AMAPTALDH1A1
SCHEMBL2062914 0.73 KEAP1 (0.56) HRH1MAPTNPSR1KEAP1NFE2L2
SCHEMBL2062409 0.73 KEAP1 (0.56) HRH1MAPTNPSR1KEAP1NFE2L2
SCHEMBL15283226 0.73 LMNA (0.63) MEN1LMNAKMT2AMAPTNPSR1
SCHEMBL25237522 0.73 SMN1; SMN2 (0.48) MEN1KMT2ASMN1; SMN2CHRM3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116836104-A Blue light induced method for hydrogen trifluoromethyl of alkynyl compound 湖南大学 2023-10-03 CN disclosed
US-8557828-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBVIE INC. (US) 2013-10-15 US disclosed
EP-2500347-A1 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme Abbott Laboratories (US) 2012-09-19 EP disclosed
EP-2142552-B1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LAB (US) 2012-08-01 EP disclosed
US-20120041003-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2012-02-16 US disclosed
US-8076344-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBOTT LABORATORIES (US) 2011-12-13 US disclosed
EP-2142552-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME Abbott Laboratories (US) 2010-01-13 EP disclosed
US-20080293713-A1 Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme ABBOTT LABORATORIES (US) 2008-11-27 US disclosed
WO-2008134690-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-11-06 WO disclosed
EP-0540690-B1 PHOTOCHROMIC CHROMENE COMPOUNDS PPG INDUSTRIES INC (US) 1996-05-29 EP disclosed
WO-1992001959-A1 PHOTOCHROMIC CHROMENE COMPOUNDS PPG INDUSTRIES, INC. (US) 1992-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041003-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME DGAT1, DGAT2, LCAT MEN1 3241/4885LMNA 4304/4885CYP2D6 1008/4885
US-20080293713-A1 Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme DGAT1, DGAT2, LCAT MEN1 3241/4885LMNA 4304/4885CYP2D6 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.